The initial treatment of Parkinson's disease should begin with levodopa

Movement Disorders

Volumn 14, Issue 5, 1999, Pages 716-724

  Weiner, William J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine receptor agonists; Levodopa; Levodopa sparing strategies; Parkinson's disease; Toxicity

Indexed keywords

BOLDENONE UNDECENOATE; BROMOCRIPTINE; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ROPINIROLE;

DRUG CHOICE; DYSKINESIA; HUMAN; MENTAL DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

AGED; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; BROMOCRIPTINE; DRUG THERAPY, COMBINATION; ESSENTIAL TREMOR; FEMALE; HUMANS; INDOLES; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PERGOLIDE; RECEPTORS, DOPAMINE; THIAZOLES; TIME FACTORS;

EID: 0032737057     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q     Document Type: Review

References (60)

1. Yahr MD. Evaluation of long-term therapy in Parkinson's disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O, eds. Advances in Parkinsonism. Basel: Editions Roche, 1976:444-455.
2. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson's mortality with early versus late dopa treatment. Ann Neurol 1987;22:8-12.
3. Scigliano G, Musicco M, Soliveru P, et al. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. Neurology 1990;40:265-269.
4. Fahn S. Is levodopa toxic? Neurology 1996;47(suppl 3):S184-195.
5. Agid Y. Levodopa - is toxicity a myth? Neurology 1998;50:858-863.
6. Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of levodopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195.
7. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984;43:990-993.
8. Sahakian BJ, Carlson KR, DeGirolaml U, Bhawan J. Functional and structural consequences of long term dietary L-dopa treatment in mice. Commun Psychopharmacol 1980;4:169-170.
9. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-133.
10. Dziewczapolski G, Murer G, Agid Y, Gershanik O, Raisman-Vosari R. Absence of neurotoxicity of chronic L-dopa treatment in 6-hydroxydopamine lesioned rats. Neuroreport 1997;8:975-979.
11. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
12. Rajput AH, Fenton ME, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997;12:634-638.
13. Yahr MD, Wolf A, Antunes JL, Miyoshi K, Duffy P. Autopsy findings in parkinsonism following treatment with levodopa. Neurology 1972;22(suppl):56-71.
14. Peppe A, Dambrosia JM, Chase T. Risk factors for motor response complications in L-dopa-treated parkinsonian patients. Adv Neurol 1993;60:698-702.
15. Chase TN, Mouradian MM, Engber T. Motor response complications and the function of striatal efferent systems. Neurology 1993; 43(suppl 6):S23-27.
16. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
17. Calne DB, Stossl J. Approaches to the use of bromocriptine in Parkinson's disease. In: Fahn S, Marsden CD, Jenner P, Teychenne P, eds. Recent Developments in Parkinson's Disease. New York, NY: Raven Press, 1986:255-258.
18. Grimes JD, Hassan MN. Evidence to support the simultaneous initiation of dopamine agonist and levodopa therapy in the management of patients with Parkinson's disease. Arch Neurol 1988; 45:206.
19. Monastruc JL, Rascol O, Rascol A. A randomized controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a 3 year follow up. J Neurol Neurosurg Psychiatry 1989;52:324-328.
20. Hely MA, Morris JGL, Rail D, et al. The Sidney multicentre study of Parkinson's disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry 1989;52:324-328.
21. U.K. Bromocriptine Research Group. Bromocriptine in Parkinson's disease: a double blind study comparing 'low-slow' and 'high-fast' introductory dosage regimens in de novo patients. J Neurol Neurosurg Psychiatry 1989;52:77-82.
22. Olanow CW, Alberts MJ, Stajich J, Birch G. A randomized blinded study of low dose bromocriptine versus low dose carbidopa/ levodopa in untreated Parkinson's disease. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinson's Disease, vol 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:201-208.
23. Riopelle RJ, Gravel M, Libman I, et al. A double blind study of bromocriptine and L-dopa in de novo Parkinson's patients: results of 6 months. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinson's Disease, vol 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:215-219.
24. Staal-Schreinemachers AL, Wessling H, Kamphuis DJ, Burg W, Lakke JPWF. Low dose bromocriptine therapy in Parkinson's disease: double blind placebo controlled study. Neurology 1986;36: 291-293.
25. Hershovits E, Yprio A, Herrera E, et al. Use of bromocriptine in 'de novo' parkinsonian patients. Adv Therapy 1986;3:29-38.
26. Lieberman AN, Goldstein M. Bromocriptine in Parkinson's disease. Pharmacol Rev 1985;37:217-227.
27. Nakanishi T, Mizurio Y, Goto I, et al. A nationwide collaborative study on long-term effects of bromocriptine in patients with Parkinson's disease: the fourth interim report. Eur Neurol 1991;31 (suppl 1):3-16.
28. Factor SA, Weiner WJ, Sanchez-Ramos J, et al. Double-blind comparison of bromocriptine and levodopa/carbidopa both alone and in combination in de novo Parkinson patients. Neurology 1991;41 (suppl 1):172.
29. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985;35:1196-1198.
30. Hely MA, Morris JGL, Reid WGJ, et al. The Sidney Multicenter Study of Parkinson's disease: a randomized, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994;57:903-910.
31. Kurlan R. International symposium on early dopamine agonist therapy of Parkinson's disease. Arch Neurol 1988;45:204-208.
32. Factor SA. Dopamine agonists. Med Clin North Am 1999;83:415-443.
33. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993;8: 257-262.
34. Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990;40(suppl 3):50.
35. Cedarbaum JM, Gandy SE, McDowell FH. 'Early' initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 1991;41:622-629.
36. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29:1253-1260.
37. De Jong GT, Meerwaldt JD, Schmitz PIM. Factors that influence the occurrence of response variations in Parkinson's disease. Neurology 1990;40:1344-1346.
38. Blin J, Bonnet AM, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988;38:1410-1416.
39. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991;41:380-384.
40. Roos RAC, Vredevoogd CB, van der Velde EA. Response fluctuations in Parkinson's disease. Neurology 1990;40:1344-1346.
41. Rajput AH, Stern W, Laverly WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984;34:991-996.
42. Rascol A, Olsson JE, Worm-Petersen J, et al. Early combination of bromocriptine with levodopa in the treatment of Parkinson's disease: a five-year multicentric sudy. Mov Disord 1994;9(suppl 1): 102.
43. Monstastruc JL, Rascol O, Senard JM, et al. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
44. Fischer PA, Przuntek H, Majer M, et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
45. Moore AP, Bakheit M, Henderson L, et al. Early combination of bromocriptine with levodopa in the treatment of Parkinson's disease: a five year double blind study. Ann Neurol 1994;36:281A (P85).
46. Nakanishi T, Iwata M, Goto I, et al. Nationwide collaborative study on the long term effects of bromocriptine in the treatment of parkinsonian patients: final report. Eur Neurol 1992;32(suppl 1): 9-22.
47. Nakashini T, Mizuno Y, Goto I, et al. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease: first interim report in Japan. Eur Neurol 1988; 28(suppl 1):3-8.
48. Weiner WJ, Factor SA, Sanchez-Ramos JR, et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993;43:21-27.
49. Rinne UK. Early dopamine agonist therapy in Parkinson's disease. Mov Disord 1989;4(suppl 1):S86-S94.
50. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995;45(suppl 3):S13-S21.
51. Wolters ECH, Tissingh G, Bergmans PLM, et al. Dopamine agonists in Parkinson's disease. Neurology 1995;45(suppl 3): S28-S34.
52. Kulisevsky J, Lopez-Villegas D, Garcia-Sanchez C, Barbanoj M, Gironell A, Pascual-Sedano B. A six month study of pergolide and levodopa in de novo Parkinson's disease patients. Clin Neuropharmacol 1998;21:358-362.
53. Lledo A, Quail D, Teus van Laar, Windlesham, Surrey, Vreeling F, Maastricht, Barone P. An analysis of the efficacy and safety of pergolide monotherapy in the treatment of Parkinson's disease. Presented at the American Academy of Neurology 51st Annual Meeting; Toronto, Canada; April 1999.
54. Shannon KM, Bennett JP, Friedman JH, et al. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-728.
55. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease: a randomized dose-ranging study. JAMA 1997;278:125-130.
56. Carrion A, Weiner WJ, Shulman LM. A three and a half year experience with pramipexole monotherapy in patients with early Parkinson's disease. Neurology 1998;50:A330.
57. Bressman SB, Shulman LM, Tanner CM, Rajput AH, Shannon KM, Wright E. Long-term safety and efficacy of pramiepexole in early Parkinson's disease. Presented at the American Academy of Neurology 51st Annual Meeting; Ontario, Canada; April 1999.
58. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49:393.
59. Sethi KD, O'Brien CF, Hammerstad JP, et al. Ropinirole for the treatment of early Parkinson's disease: a 12 month experience. Ropinirole Study Group. Arch Neurol 1998;55:1211-1216.
60. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord 1998;13:39.